Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:52:02.408Z.
Calculation as of: 2026-10-06T18:52:02.408Z.
Quote observation: 2026-10-06T18:49:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$988.20M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$988.52M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$990.27M
Price/OCF Ratio
72.34
TTM Avg
103.87
3Y Avg
103.87
5Y Avg
103.87
Market Cap
$985.00M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$979.09M
Price/OCF Ratio
5.22
TTM Avg
6.80
3Y Avg
7.11
5Y Avg
11.19
Market Cap
$1.01B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $988.20M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $988.52M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $990.27M | 72.34 | 103.87 | 103.87 | 103.87 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $985.00M | N/A | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $995.31M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $979.09M | 5.22 | 6.80 | 7.11 | 11.19 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 78.34 | 28.91 | 23.78 |
| Aktis Oncology, Inc. (AKTS)vs › | $966.36M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $953.94M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
